Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Clinigen acquires Idis to create new leader in unlicensed medicines

This article was originally published in Scrip

Executive Summary

UK pharma service provider Clinigen is to acquire Idis for £225m to create a new market leader in the supply of unlicensed ethical medicines. Weybridge, UK-based Idis supplies unlicensed medicines mainly on an exclusive basis through managed access programs and on-demand through its general access division. It had unaudited revenues of £196.8m and adjusted EBITDA of £15.6m for the 12 months ended 28 February 2015. Clinigen says the deal will be immediately accretive and should significantly enhance earnings in the first year and further in 2017. It has also identified annual cost synergies from the acquisition of approximately £2.5m million, and believes that opportunities for further revenue and cost synergies are likely to be identified. The acquisition will be funded by a vendor placing to raise £135m and by £104m drawn from new debt facilities. Clinigen CEO said: "This acquisition satisfies a number of our key strategic goals – achieving the market leader position in the $5bn+ unlicensed medicine supply sector and strengthening our leading position in the $2bn clinical trial supply market."





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts